Metabolic effects of antihypertensive drugs

被引:0
作者
Suter, PM [1 ]
Vetter, W [1 ]
机构
[1] UNIV ZURICH HOSP, MED POLICLIN, DEPT MED, CH-8091 ZURICH, SWITZERLAND
关键词
hypertension; metabolic effects; dyslipidaemia; glucose intolerance;
D O I
暂无
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Effects of antihypertensive drugs on metabolism: Numerous antihypertensive drugs have been reported to cause adverse metabolic effects such as glucose intolerance and abnormal lipid metabolism. Diuretics: There is a well defined relationship between diuretic treatment and impaired glucose tolerance and dyslipidaemia. These effects, which are seen with thiazide diuretics and loop diuretics but not with spironolactone, are independent of body weight but are strongly dose-related. beta-Blocking agents: beta-Blockers without intrinsic sympathomimetic activity have adverse effects on lipid metabolism, but beta-blockers with intrinsic sympathomimetic activity do not. From the metabolic point of view, the latter type of beta-blockers represent the ideal choice, but they are rarely used today. All types of beta-blockers can cause an increase in fasting blood glucose and impaired glucose tolerance. Angiotensin converting enzyme (ACE) inhibitors and calcium antagonists: Neither ACE inhibitors nor calcium antagonists show any negative effects on glucose and/or lipid metabolism. ACE inhibitors have even been shown to improve insulin sensitivity ACE inhibitors and calcium channel blockers are metabolically neutral, and there is evidence that combining an ACE inhibitor or calcium antagonist with a diuretic can reduce the adverse effects of the latter. Anti-oxidation: Some calcium antagonists show a dose-dependent anti-oxidative activity. Lacidipine has the greatest anti-oxidative activity of the commonly used calcium channel blockers. Among ACE inhibitors, only captopril has anti-oxidative activity. Other factors: Both genetic and modifiable factors may contribute to the metabolic effects of antihypertensive drugs.
引用
收藏
页码:S11 / S17
页数:7
相关论文
共 73 条
[1]   GLUCOSE-INTOLERANCE DURING DIURETIC THERAPY IN ELDERLY HYPERTENSIVE PATIENTS - A 2ND REPORT FROM THE EUROPEAN WORKING PARTY ON HIGH BLOOD-PRESSURE IN THE ELDERLY [J].
AMERY, A ;
BIRKENHAGER, W ;
BRIXKO, P ;
BULPITT, C ;
CLEMENT, D ;
DERUYTTERE, M ;
DESCHAEPDRYVER, A ;
FAGARD, R ;
FORETTE, F ;
FORTE, J ;
HAMDY, R ;
LEONETTI, G ;
OMALLEY, K ;
MURPHY, M ;
PETRIE, J ;
TUOMILEHTO, J ;
WEBSTER, J ;
WILLIAMS, B .
POSTGRADUATE MEDICAL JOURNAL, 1986, 62 (732) :919-924
[2]   RAISED SERUM-LIPID CONCENTRATIONS DURING DIURETIC TREATMENT OF HYPERTENSION - STUDY OF PREDICTIVE INDEXES [J].
AMES, RP ;
HILL, P .
CLINICAL SCIENCE AND MOLECULAR MEDICINE, 1978, 55 :S311-S314
[3]  
AMES RP, 1982, J CARDIOVASC PHARM, V4, pS206
[4]   THE EFFECTS OF ANTIHYPERTENSIVE DRUGS ON SERUM-LIPIDS AND LIPOPROTEINS .2. NON-DIURETIC DRUGS [J].
AMES, RP .
DRUGS, 1986, 32 (04) :335-357
[5]   EFFECT OF CHRONIC TREATMENT WITH ENALAPRIL ON GLUCOSE-TOLERANCE AND SERUM-INSULIN IN NON-INSULIN-RESISTANT JAPANESE PATIENTS WITH ESSENTIAL-HYPERTENSION [J].
BABA, T ;
KODAMA, T ;
ISHIZAKI, T .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1993, 45 (01) :23-27
[6]   PROPRANOLOL AND HYPERTRIGLYCERIDEMIA [J].
BARBORIA.JJ ;
FRIEDBER.HD .
ATHEROSCLEROSIS, 1973, 17 (01) :31-35
[7]   LONG-TERM EXPERIENCE WITH INDAPAMIDE [J].
BELING, S ;
VUKOVICH, RA ;
NEISS, ES ;
ZISBLATT, M ;
WEBB, E ;
LOSI, M .
AMERICAN HEART JOURNAL, 1983, 106 (01) :258-262
[8]   METABOLIC CONSIDERATIONS IN THE CHOICE OF THERAPY FOR THE PATIENT WITH HYPERTENSION [J].
BLACK, HR .
AMERICAN HEART JOURNAL, 1991, 121 (02) :707-715
[9]   CHLORTHALIDONE ATTENUATES THE REDUCTION IN TOTAL CHOLESTEROL AND SMALL, DENSE LDL CHOLESTEROL SUBCLASS ASSOCIATED WITH WEIGHT-LOSS [J].
BRADLEY, K ;
FLACK, JM ;
BELCHER, J ;
ELMER, P ;
MILLER, P ;
GRIMM, R .
AMERICAN JOURNAL OF HYPERTENSION, 1993, 6 (07) :636-639
[10]  
BRECKENR.A, 1967, LANCET, V1, P61